The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020crobial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Unmet Medical Need


The World is Dangerously Underinvesting in New Antifungal Drugs.


 

Only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Meanwhile, the use of already marketed antifungals continues to increase, not least because of their extended use as fungicides in agricultural and livestock production.

Not surprisingly, Multidrug Resistance (MDR) is emerging as a serious global health threat for several fungal strains. This paradoxical situation has only intensified as the pharmaceutical industry focuses its attention on more lucrative medical indications such as cancer, cardiovascular- and neurological diseases. Indeed, over the last few years several global pharmaceutical companies have left the antimicrobial and antifungal field entirely.

Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches. Cold Spring Harb Perspect Med 2014, 4
Nature Outlook, October 21, 2020: Why big pharma has abandoned antibiotics

 


Biosergen Addresses One of the Worst Unmet Medical Needs: Invasive Fungal Diseases

Opportunistic fungal infections

Are increasing because the number of people with weakened immune systems continues to increase
Majority of systemic fungal infection-related deaths are caused by four fungal pathogens: Candida, Aspergillus, Cryptococcus and Pneumocystis

 

 

Hospital acquired infections

Has multiple causes, including inadequate sanitation protocols and the routine use of antifungal drugs that creates a selection pressure for the emergence of resistant strains
Emerging multidrug resistant (MDR) fungal pathogens


Community acquired infections

These outbreaks are almost certainly linked to demographic changes and climate change
Big-pharma has been pulling out

 

This situation is now recognized by the WHO, CDC and others as a global health threat